secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001493152-23-029903
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer
--------------------------------------------------------------------------------

- Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.
- Trial: Phase 2b/3 of TGF-β2 antisense OT-101 + FOLFIRINOX vs FOLFIRINOX alone in advanced/metastatic pancreatic cancer.
- Multinational trial targeting up to 500 patients across USA, EU, and China.
- Oncotelic CEO states TGFβ2 suppression may more than double survival in pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/0001493152-23-029903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer